Title: Cellular Atypia as a Risk Factor for Persistant Trophoblastic Disease: Prospective Cohort Study

Authors: Dr Uma Thankam, Dr Nandini Vamadevan Retnamma, Dr Simi Jameela, Dr Nirmala Chellamma

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i6.153

Abstract

Introduction: Gestational trophoblastic tumours have varying behavior from being locally invasive to metastatic. It would be useful if there is an effective prognosticating method especially in low resource settings. This study was an attempt to identify such a prognosticator.  

Aim:  To look for the presence of atypical cells in the histopathology of vesicular mole, the βhCG level four week after evacuation and look for any association with   persistent trophoblastic disease (PTD)

Material and Methods:  It was hospital based prospective cohort study conducted in a tertiary care hospital. 95 cases of vesicular mole were studied .The patients had a pre evacuation βhCG done and underwent suction curettage. The products were sent for histopathologic examination and apart from identifying the grade of proliferation they were specifically examined for presence of atypical cells. The βhCG levels four weeks after evacuation was checked.

Results: On looking at the distribution of atypical cells with βhCG four weeks after evacuation, it is seen that of the 90.6% of the patients with cellular atypia had abnormal levels of status four weeks βhCG levels. With regards to the distribution of atypical cells with the time needed to reach baseline βhCG ,out of the 32 patients with atypical cells 23  (71.9%) had an abnormal βhCG fall.

Conclusion: Looking for the presence of atypical cells in the histopathology of vesicular mole can prognosticate the nature of regression of the tumor and help in classifying it as high risk and low risk.

Keywords: cellular atypia, persistent trophoblastic disease.

References

1.      Jeffcoate’s principles of Gynaecology 8th International edition 2014

2.      Ross S Berkowitz, Donald P Goldstein, Jonathan S Berck “Gestational Trophob-lastic  Diseases” Novak’s Gynaelogy Fourteenth edition 2008

3.      Buckley, Jonathan D “The Epidemiology of molar pregnancy and choriocarcinoma” Clinical Obstetrics and Gynaecology, Vol:27,No.1 1984 153-158

4.      Yen S , ;Mac Mahon.B “Epidemiology features of trophoblastic diease” AJOG 1968,101:126

5.      Keith Edmunds D “Gestational Trophoblastic Diseases” Dewhurst’s Text book of Obstetrics and Gynaecology for postgraduates 6th edition(2000) 61-75

6.      Robin P Farias ,Eisner, Jonathan .S.Berek ,Manual of clinical oncology 4th edition (2000) 264-68

7.      Gary Cunningham F ,Paul C Mcdonald, Norman F. Grant “Trophoblastic Diseases” Williams Obstetrics 20th edition (1998) 669-693

8.      Richard H .J .Begent, Kenneth D. Bagshawe :Treatment of Advanced Trophoblastic Disease: Gynaecologic Oncology :Vol10 cancer treatment and research pp155-186

9.      Park WW. :Choriocarcinoma A study of its pathology London Heinemann 1971

10.  P.Balaram, M.John,T.N.Rajalekshmy, A. Mathew, S.Enose, V.P.Gangadharan.”A Multivariate analysis of prognostic indicators in complete hydatidiform moles” European Journal of Obstetrics and Gynecology  and Reproductive Biology: 87: 1999;69-75

11.  John R. Lurain MD, Lisa A Casanova MD, David Sott Miller MD, Alfred W.Rademaker PhD Prognostic factors in gestational trophoblastic tumors: A proposed new scoring system based on mulivariate analysis AJOG Vol 164, Issue 2,Feb 1991, Pages 611-616

12.  Hertig AT, Sheldon WH “Hydatidiform Mole: A pathologic-clinical correlation of 200 cases “ AJOG (1947)53:1

13.  Tow, W. S. H., and Yung, R.H.(1967), The value of histological grading in prognosticating of hydatidiform mole.J. Obtet.Gynae.Brit.Cwlth 74,292 191

Elston CW “The Histopathology of Trophoblastic Tumours” J Clin Pathology(1976):10(suppl):111  

Corresponding Author

Dr Uma Thankam

Assistant Professor, Department of Obstetrics & Gynecology, SAT Hospital, Government Medical College, Thiruvananthapuram

Mobile: 9446505656    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.